Impact Biomedicines, Inc.

The quarterly Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA) reported biopharma start-ups raised $5.9bn in the first quarter of 2024 – more than the sector r

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo

Cardiovascular, cancer and other concerns forced the US Food and Drug Administration to limit the use of several JAK inhibitors to patients who cannot tolerate one or more TNF blockers. Based on a rev

Bristol Myers Squibb Company 's Inrebic has become the first new therapy in the EU in nearly a decade to get the green light for myelofibrosis (MF), joining Novartis AG and Incyte Corporation 's Ja